Bristol-Myers Squibb offers strong cash flow, solid growth, and a high yield despite pricing pressure and pipeline risks. Read why BMY stock is a buy.

Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) fell 4.2% in the afternoon session after the company lowered its full-year earnings forecast, overshadowing second-quarter results that beat revenue expectations.

Over the past five years, BMY's one-day stock returns following earnings announcements have been evenly split:

Myers Squibb (NYSE:BMY) shares inched up on Friday after six consecutive sessions of fall. The stock was up 2.2% at $44.24. BMY’s shares lost nearly 11.6% in the preceding six sessions. On a year-to-date basis,

Shares of Bristol Myers Squibb Co. BMY slid 5.81% to $43.31 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 0.37% to 6,339.39 and Dow Jones Industrial Average DJIA falling 0.74% to 44,130.98.

Bristol-Myers Squibb Company (($BMY)) has held its Q2 earnings call. Read on for the main highlights of the call. Bristol-Myers Squibb’s recent

Investors weren't impressed with Bristol-Myers Squibb Company's (BMY) Q2 2025 results, with the stock down by 5.8% after earnings. Read the latest stock analysis here.

This was the stock's fifth consecutive day of losses.

B ullish option flow detected in Bristol Myers Squibb with 19,247 calls trading, 3x expected, and implied vol increasing almost 2 points to 30.67%. Aug-25 45 calls and Sep-25 44 p